Pfizer Trades at 8–9× Forward Earnings with 7% Yield and Seagen Upside
Pfizer trades at 8–9× forward earnings with a nearly 7% dividend yield, reflecting undervaluation relative to the industry. Recent Seagen acquisition is projected to generate over $10 billion in annual revenue by 2030, while cost-cutting measures and a strong core product portfolio aim to sustain margins despite post-COVID declines.
1. Valuation and Dividend
Pfizer’s stock is currently valued at 8–9× forward earnings, significantly below industry averages. The company offers a nearly 7% dividend yield, supported by its cash flow even after post-COVID revenue declines.
2. Seagen Acquisition Outlook
Pfizer completed its Seagen acquisition to bolster its oncology portfolio, with Seagen revenue forecast to exceed $10 billion annually by 2030. This transaction positions Pfizer for long-term growth in high-margin cancer therapies.
3. Cost-Cutting and Portfolio Strength
Management has implemented cost-cutting initiatives aimed at improving operating margins and offsetting lower COVID vaccine sales. A diversified core portfolio spanning immunology, rare diseases and vaccines provides stability while new pipeline assets advance.